arrow
H

Hannelore Denys

ghent university hospital
H指数:42
被引数:8,400

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP)

乳腺癌术中切缘评估(使用标本PET-CT)(BIMAP)

2025-09-260
OAAI
Uterine Leiomyosarcoma

子宫平滑肌肉瘤

2025-06-300
PRE
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study

VB10.16治疗性DNA疫苗与atezolizumab联合用于持续性、复发性或转移性HPV16阳性宫颈癌的安全性和有效性:一项多中心、单臂2a期研究

2025-01-071
OA
Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)

III期ATALANTE/ENGOT-ov29试验最终总生存期(OS)结果,该试验评估了在铂敏感复发的卵巢癌(OC)患者(pts)中,阿替利珠单抗(Atz)与安慰剂联合标准化疗(Cx)加贝伐珠单抗(bev)的比较。

2024-09-011
PRE
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
2024-08-010
PRE
Efficacy and Safety of Alpelisib in PIK3CAmutated, hormone receptorpositive advanced breast cancer after a CDK4/6 inhibitor: An Openlabel, Multi-centre, Prospective, Single Arm Clinical Trial
2024-05-020
PRE
Effects of hyperthermia on cisplatin tissue penetration and gene expression in peritoneal metastases: results from a randomized trial in ovarian cancer

热疗对腹膜转移的顺铂组织渗透和基因表达的影响: 卵巢癌随机试验的结果

2024-04-241
PRE
CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006)
2024-04-050
PRE
Identification and validation of extracellular vesicle reference genes for the normalization of RT-qPCR data

用于rt-qpcr数据归一化的胞外囊泡参考基因的鉴定和验证

2024-03-282
OA